^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    PD-L1 expression

    i
    Other names: PD-L1, CD274, HPD-L1, PD-L1, B7H1, PDL1, Programmed death ligand 1, B7-H1, B7-H, PDCD1L1, PDCD1LG1, PDCD1 Ligand 1, B7 homolog 1, CD274 Antigen, Programmed cell death 1 ligand 1, CD274 molecule
    Entrez ID:
    29126
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    Related tests:
    1d
    CD8/CD4 ratio, CD56, and PD-L1 as prognostic markers in sinonasal mucosal melanoma. (PubMed, Int J Clin Oncol)
    Immune markers, particularly the CD8/CD4 ratio and CD56-positive lymphocytes, were significantly associated with survival outcomes independent of traditional histopathologic factors. Incorporating immune profiling into risk stratification may improve prognostication and guide the development of immune-targeted strategies in SNMM.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • NCAM1 (Neural cell adhesion molecule 1)
    |
    PD-L1 expression
    2d
    PEMDA-HN: Activity and Safety of Danvatirsen and Pembrolizumab in HNSCC (clinicaltrials.gov)
    P2, N=69, Terminated, Flamingo Therapeutics NV | Trial completion date: May 2026 --> Aug 2025 | Recruiting --> Terminated; Interim analysis was negative
    Trial completion date • Trial termination
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • danvatirsen (AZD9150)
    2d
    A Study to Compare Uliledlimab Combined With Toripalimab, Toripalimab Monotherapy, and Pembrolizumab Monotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1- and CD73- Selected Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2/3, N=450, Active, not recruiting, TJ Biopharma Co., Ltd. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • CD73 (5'-Nucleotidase Ecto) • NT5E (5'-Nucleotidase Ecto)
    |
    PD-L1 expression
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Keytruda (pembrolizumab) • Loqtorzi (toripalimab-tpzi) • uliledlimab (TJD5)
    2d
    A Study to Compare Uliledlimab Combined With Sintilimab and Chemotherapy Versus Sintilimab Combined With Chemotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic Non-small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=150, Active, not recruiting, TJ Biopharma Co., Ltd. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    PD-L1 (Programmed death ligand 1) • CD73 (5'-Nucleotidase Ecto) • NT5E (5'-Nucleotidase Ecto)
    |
    PD-L1 expression
    |
    PD-L1 IHC 22C3 pharmDx
    |
    cisplatin • carboplatin • gemcitabine • Tyvyt (sintilimab) • pemetrexed • uliledlimab (TJD5)
    2d
    PD-L1 status on circulating tumor cells: a promising predictor in advanced lung cancer with PD-1/PD-L1 immunotherapies. (PubMed, Eur J Med Res)
    We developed a novel procedure to detect and characterize PD-L1 expression on CTCs, which was a feasible, non-invasive biomarker for potentially predicting the combination of chemotherapy and immunotherapy efficacy in advanced lung cancer, addressing tissue sampling limitations and enhancing patient stratification and monitoring.
    Journal • Circulating tumor cells • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C)
    |
    PD-L1 expression
    2d
    French recommendations for clinical practice, Nice-Saint-Paul de Vence 2024-2025: Management of advanced cervical cancer (PubMed, Bull Cancer)
    Since 2022, immunotherapy is part of standard therapeutic strategy with pembrolizumab on the one hand, associated with chemotherapy and bevacizumab in patients with PD-L1 positive tumors (CPS≥1), and cemiplimab on the other hand, in patients who did not receive prior immunotherapy and progress after first line regardless of PD-L1 expression. Whenever possible, molecular screening and determination of HER2 status may allow orienting patients to clinical trials. Indeed, inclusion in investigational studies must be systematically considered and early supportive care is always recommended.
    Clinical guideline • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • Libtayo (cemiplimab-rwlc)
    2d
    Circular RNA-Mediated Tumor Immune Escape: Mechanistic Architecture and Nanomedicine-Enabled Therapeutic Reprogramming. (PubMed, Crit Rev Oncol Hematol)
    Although challenges remain, including delivery specificity, biosafety, biomarker standardization, and off-target effects, the convergence of circRNA biology and advanced nanotechnology presents a transformative opportunity to develop next-generation RNA-guided cancer immunotherapies. Together, these findings position circRNAs as both key mechanistic drivers of immune escape and promising therapeutic targets for nanomedicine-enabled precision immunotherapy.
    Review • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8)
    |
    PD-L1 expression
    3d
    The safety and efficacy of cryoablation combined with immune checkpoint inhibitors in advanced non-small cell lung cancer (ChiCTR2600117360)
    P=N/A, N=40, Not yet recruiting, The First Affiliated Hospital, College of Medicine, Zhejiang University; The First Affiliated Hospital, College of Medicine, Zhejiang University
    New trial
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    PD-L1 expression
    3d
    A Single-Arm Prospective Clinical Study on the Efficacy of Neoadjuvant Therapy with Toripalimab Combined with TP Regimen for Locally Advanced Head and Neck Tumors (ChiCTR2600117056)
    P=N/A, N=30, Not yet recruiting, The First People's Hospital of Yunnan Province; The First People's Hospital of Yunnan Province
    New trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    cisplatin • Loqtorzi (toripalimab-tpzi) • albumin-bound paclitaxel
    3d
    A Prospective, Single-Arm, Dual-Center Study on the Efficacy and Safety of Cryoablation Combined with Neoadjuvant Immunotherapy and Chemotherapy for Resectable Stage II-IIIB Non-Small Cell Lung Cancer (ChiCTR2600116611)
    P=N/A, N=30, Not yet recruiting, The First Affiliated Hospital of Soochow University; The First Affiliated Hospital of Soochow University
    New trial
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    PD-L1 expression • EGFR wild-type • ALK wild-type
    3d
    This study aims to evaluate the efficacy and safety of Disitamab Vedotin combined with Cisplatin and Candelinib in the treatment of patients with locally advanced cervical cancer. (ChiCTR2500114983)
    P=N/A, N=30, Recruiting, Dalian Medical University Second Affiliated Hospital; Dalian Medical University Second Affiliated Hospital
    New trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression • HER-2 expression
    |
    cisplatin • Aidixi (disitamab vedotin) • Kaitanni (cadonilimab)
    3d
    Clinical study on the safety and efficacy of sintilimab combined with chemotherapy in neoadjuvant treatment of locally advanced rectal cancer (ChiCTR2500114358)
    P=N/A, N=41, Recruiting, The First Affiliated Hospital of Anhui Medical University; The First Affiliated Hospital of Anhui Medical University
    New trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Tyvyt (sintilimab) • capecitabine • oxaliplatin